Drug Development Phase 3 Trials Cancer Treatment Drug Approval Phase I Trials Research Studies Human Trials Drug Trials Cancer Research Drug Testing Drug Efficacy Patient Care Combination Therapy Phase 2 Trial Gene Therapy Trials Preclinical Studies Innovative Treatments Research Preclinical Research Randomized Controlled Trials Phase 1 Trials Drug Safety Ketamine Ketamine Treatment GLP-1 Treatments Therapeutic Discoveries Therapeutics Product Development Longevity Science FDA Approvals Behavioral Health Study Results Impotence Drug Efficacy and Safety Pain Relief Adverse Events Opioids Tirzepatide Drug Effects Xolair Experimental Treatments Late-Stage Clinical Trial Severe Frostbite Obesity Drug Trials ALS Treatment Cardiovascular Disease Trials Side Effects Medication Trials CAR T-cell Therapy Phase 1 Clinical Trial New Drug Formulations Phase 2 Phase Two Trial Gene-Edited Organ Transplants Experimental Treatment Phase 2a Clinical Trial ALS Drug Trials PHOENIX Study Phase Three Trials Stage 3 Clinical Trials Phase 1b/2a RUBY Study Drug Approval Process Phase-Two Trial Phase-Three Trials Animal Trials Cardiology Vaccine Trials Pediatric Trials Safety Studies Cancer Therapies Patient Studies Animal Models Phase 2 Trials Phase 1/2 Trials Patient Stratification Cancer Treatments Cancer Treatment Strategies Cell Therapy Neoadjuvant Therapy DREAMM Trials Animal Studies Infectious Diseases Phase II Trials Pharmacology Pivotal Studies Medical Treatments Regulatory T-cells Phase III Trials Autoimmune Diseases Patient-Derived Models Efficacy Studies Early-Stage Clinical Trial Select Trial Obesity Weight Loss Clinical Trial Findings Neural Activity Research Findings Research Funding Phase 3 Trial
A Nature Cancer report describes a single-dose HSV-1 platform that reprogrammed the tumor microenvironment, prolonging survival in mouse models.
